Abstract:CDK2, which interacts with cyclin A and cyclin E, is an important member of the CDK family. Having been proved to be associated with many diseases for its vital role in cell cycle, CDK2 is a promising target of anti-cancer drugs dealing with cell cycle disorders. In the present work, a total of 111 pyrazolo[1,5-a]pyrimidines (PHTPPs) as CDK2/cyclin A inhibitors were studied to conduct three-dimensional quantitative structure-activity (3D-QSAR) analyses. The optimal comparative molecular similarity indices analysis (CoMSIA) model shows that Q(2) = 0.516, R-ncv(2) = 0.912, R-pre(2) = 0.914, R-m(2) = 0.843, SEP = 0.812, SEE = 0.347 with 10 components using steric, hydrophobic and H-bond donor field descriptors, indicating its effective internal and external predictive capacity. The contour maps further indicate that (1) bulky substituents in R-1 are beneficial while H-bond donor groups at this position are detrimental; (2) hydrophobic contributions in the R-2 area are favorable; (3) large and hydrophilic groups are well tolerated at the R-3 position (a close H-bond donor moiety is favorable while a distal H-bond donor moiety in this area is disfavored); (4) bulky and hydrophobic features in the R-4 region are beneficial for the biological activities and (5) the 7-N-aryl substitution is crucial to boost the inhibitory activities of the PHTPP inhibitors. Finally, docking and MD simulations demostrate that PHTPP derivatives are stabilized in a 'flying bat' conformation mainly through the H-bond interactions and hydrophobic contacts. Comparative studies indicate that PHTPP derivatives fit well within the ATP binding cleft in CDK2, with the core heterocyclic ring overlapping significantly with the adenine group of ATP despite a small deflection. In comparison to numerous other inhibitors binding to the ATP pocket, PHTPP analogues follow the binding fashion of purine inhibitors of this kinase. It is anticipated that the binding mechanism and structural features of PHTPP inhibitors studied in the present work will benefit the discovery of more potent CDK2 inhibitors, and the valid pyrazolo[1,5-a]pyrimidine-7-N-yl inhibitors will soon emerge from the large number of screening programmes to enter in clinical studies.

Exploring the Structure Requirement for PKCθ Inhibitory Activity of Pyridinecarbonitrile Derivatives: an in Silico Analysis.

Structural Determinants Of Cx-4945 Derivatives As Protein Kinase Ck2 Inhibitors: A Computational Study

Insights into the structural requirements of PKC inhibitors as potential anti-arthritis agents based on 3D-QSAR, homology modeling and docking approach

Three-dimensional Quantitative Structure-Activity Relationships of Pyrrolopyridinone As Cell Division Cycle Kinase Inhibitors by CoMFA and CoMSIA.

Insight into the Structural Requirements of Benzimidazole Derivatives As Interleukin‐2 Inducible T‐cell Kinase Inhibitors by Computational Explorations

D-QSAR studies on pyrimidine analogues as cyclin-dependent kinase 1 inhibitors

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

Insights into the structural requirements of PKCζ inhibitors as potential anti-arthritis agents based on 3D-QSAR, homology modeling and docking approach

Exploring New Potential Pkcθ Inhibitors Using Pharmacophore Modeling, Molecular Docking Analysis, and Molecular Dynamics Simulations

Identification, Structure–Activity Relationships of Marine-Derived Indolocarbazoles, and a Dual PKCθ/δ Inhibitor with Potent Antipancreatic Cancer Efficacy

Development of in Silico Models for Pyrazoles and Pyrimidine Derivatives As Cyclin-Dependent Kinase 2 Inhibitors

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Structural Requirements of Pyrimidine, Thienopyridine and Ureido Thiophene Carboxamide-Based Inhibitors of the Checkpoint Kinase 1: QSAR, Docking, Molecular Dynamics Analysis.

3D-Qsar and Docking Studies on Pyrrolopyrimidine Derivatives As Lim-Kinase 2 Inhibitors

Molecular simulation of a series of benzothiazole PI3Kα inhibitors: probing the relationship between structural features, anti-tumor potency and selectivity

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110alpha inhibitors.

Using 3D-QSAR and Molecular Docking Insight into Inhibitors Binding with Complex-Associated Kinases CDK8

An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.

3D-QSAR and 3D-QSSR Studies of Thieno[2,3-D]pyrimidin-4-yl Hydrazone Analogues As CDK4 Inhibitors by CoMFA Analysis

Quantitative Structure-Activity Relationship Of Quinazoline Derivatives With The Inhibitory Activity Toward Nf-Kappa B